Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

One stock defying the market selldown

  • In Opinion
  • March 17, 2020
  • Sam Green
One stock defying the market selldown

With news that the COVID-19 virus has shut down more than 20,000 events worldwide, locked many people indoors, and caused a sell down in most commodity markets – it’s a near certainty that we will see recessionary economic growth levels for Q1 and Q2 2020.

This is causing share prices to fall at a rate that is nearly unprecedented.

However, one major stock has defied the selling, rallying while just about every other stock has been selling off.

Fisher & Paykel Healthcare Corporation Limited (FPH.ASX) is a manufacturer of healthcare products for use in respiratory care, as well as other healthcare markets.

With many COVID-19 patients requiring respirators to deal with some of the worst symptoms of the virus, such products have been in hot demand, and this is causing speculators to push FPH’s share price higher.

The company has stated that they “have seen an increase in demand globally and have ramped up our manufacturing output.”, also stating that “Our respiratory humidifiers and consumables are directly involved in treating patients with coronavirus”.

The company has upgraded its full-year profit guidance by $NZD 5-20 million, while also lifting its revenue forecast by around $NZD 40 million.

Since our ASX/S&P 200 index stated falling on the 21st of February, FPH has risen just under five percent, whilst the index has fallen nearly thirty percent over that time.

From a valuation perspective, FPH is trading at a fairly high level – its current year price to earnings ratio is more than three times the market average. Its current year dividend yield is less than a quarter of the ASX/S&P 200 dividend yield.

However, investors will be hoping that these metrics can be elevated by strong sales during these turbulent times, or at least that the earnings and dividends will hold up while those around them fall. At the very least, the stock appears a safer bet than many other businesses that will take a hit to earnings from the virus.

Is FPH a good buy to add to your portfolio? Are prices too elevated in the present time of a discounted equity market? Emerald Equities offers in-depth coverage of the Australian equity market, with stock recommendations and a plethora of fundamental information. If you are interested in hearing more about our upcoming service – please register here.

  • About
  • Latest Posts
Sam Green
Sam Green is the Portfolio Manager at Emerald Financial, whilst also being an Equities and Derivatives expert for his clients at TradersCircle.
Latest posts by Sam Green (see all)
  • XJO to rise despite slight US pullback - August 30, 2024
  • Markets jump strongly higher - July 29, 2024
  • US shares drop with tech selling, XJO to continue lower - July 25, 2024
  •  
  •  
  •  
  •  
  • asx fph
  • COVID-19
  • Fisher and Paykel Healthcare
  • FPH
  • healthcare
  • respirator manufacturer
  • Opinion

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Sam Green
Sam Green is the Portfolio Manager at Emerald Financial, whilst also being an Equities and Derivatives expert for his clients at TradersCircle.
Latest posts by Sam Green (see all)
  • XJO to rise despite slight US pullback - August 30, 2024
  • Markets jump strongly higher - July 29, 2024
  • US shares drop with tech selling, XJO to continue lower - July 25, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Sam Green
Sam Green is the Portfolio Manager at Emerald Financial, whilst also being an Equities and Derivatives expert for his clients at TradersCircle.
Latest posts by Sam Green (see all)
  • XJO to rise despite slight US pullback - August 30, 2024
  • Markets jump strongly higher - July 29, 2024
  • US shares drop with tech selling, XJO to continue lower - July 25, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.